Position in LYEL
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$1,105,506
+$826,917 QoQ
Shares Held
55,110
+508.9% QoQ
Ownership
0.236%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Dec 2025
2 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in LYEL Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Qube Research & Technologies Ltd holds $2,030,593,180 across 187 Biotechnology names. LYEL ranks #119 (0.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
838,187 | $277,330,932 | |
| 2 | FOLD |
AMICUS THERAPEUTICS, INC.
|
8,809,340 | $127,383,056 | |
| 3 | ROIV |
Roivant Sciences Ltd.
|
3,450,904 | $95,590,040 | |
| 4 | RPRX |
Royalty Pharma plc
|
1,524,511 | $73,130,792 | |
| 5 | REGN |
Regeneron Pharmaceuticals, Inc.
|
83,358 | $64,405,725 | |
| 6 | AXSM |
Axsome Therapeutics, Inc.
|
335,334 | $56,678,152 | |
| 7 | RVMD |
Revolution Medicines, Inc.
|
553,290 | $53,807,452 | |
| 8 | CYTK |
Cytokinetics Inc
|
779,446 | $51,373,285 |
All Filings in LYEL
Export CSV
2 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $1,105,506 | 55,110 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $278,589 | 9,051 | Shares | Sole | 2026-02-17 | |
| No filing history on record for this holder in this stock. | ||||||